Bronstein, Gewirtz & Grossman LLC Urges Ardent Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Impact · against what's priced in

Ardent Health faces significant valuation pressure due to a 9.6% reduction in 2025 EBITDA guidance and allegations of overstated Q3 2025 revenue. While Celsius and iTonic are mentioned as targets of separate lawsuits, the material financial disclosures are specific to Ardent Health.

ARDT−0.70

No priced-in read yet